CD38 is a transmembrane glycoprotein widely expressed on malignant plasma cells in MM, as well as on various hematopoietic and non-hematopoietic cell types, which introduces both opportunities and challenges for targeted immunotherapy. The gene discussed is CD38; the disease is Miyoshi myopathy.